BRPI1009606A2 - método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição - Google Patents
método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composiçãoInfo
- Publication number
- BRPI1009606A2 BRPI1009606A2 BRPI1009606A BRPI1009606A BRPI1009606A2 BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2 BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A BRPI1009606 A BR PI1009606A BR PI1009606 A2 BRPI1009606 A2 BR PI1009606A2
- Authority
- BR
- Brazil
- Prior art keywords
- multiple sclerosis
- treating
- microparticle
- symptoms
- linked
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title 2
- 108010016626 Dipeptides Proteins 0.000 title 1
- 239000011859 microparticle Substances 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1009606A2 true BRPI1009606A2 (pt) | 2016-10-11 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1009606A BRPI1009606A2 (pt) | 2009-06-16 | 2010-01-16 | método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (enExample) |
| EP (1) | EP2442832B1 (enExample) |
| JP (1) | JP5646617B2 (enExample) |
| CN (1) | CN102458476B (enExample) |
| AU (1) | AU2010260585B2 (enExample) |
| BR (1) | BRPI1009606A2 (enExample) |
| CA (1) | CA2688766C (enExample) |
| CY (1) | CY1115714T1 (enExample) |
| DK (1) | DK2442832T3 (enExample) |
| ES (1) | ES2521565T3 (enExample) |
| HR (1) | HRP20141035T1 (enExample) |
| IL (1) | IL216993A (enExample) |
| IN (1) | IN2012DN00167A (enExample) |
| MX (1) | MX2011013661A (enExample) |
| NZ (1) | NZ577731A (enExample) |
| PL (1) | PL2442832T3 (enExample) |
| PT (1) | PT2442832E (enExample) |
| SI (1) | SI2442832T1 (enExample) |
| SM (1) | SMT201400165B (enExample) |
| WO (1) | WO2010147484A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2719252C (en) * | 2008-04-01 | 2016-01-19 | Innate Therapeutics Limited | Anti-infective agents comprising muramyl dipeptide microparticles and uses thereof |
| JP5847188B2 (ja) | 2010-10-25 | 2016-01-20 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法 |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| HRP20250396T1 (hr) | 2016-08-31 | 2025-05-23 | Mapi Pharma Ltd. | Depo sustavi koji sadrže glatiramer acetat |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| CA3099946A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| US12109271B2 (en) | 2018-07-03 | 2024-10-08 | University Of Florida Research Foundation, Incorporated | Microparticle systems and their use for the treatment of multiple sclerosis |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2268372C (en) * | 1996-10-10 | 2012-11-27 | Probe International | Compositions and methods for treating viral infections |
| BRPI0512921A (pt) * | 2004-07-01 | 2008-04-22 | Den Kgl Veterinaer Og Landboho | processo para tratamento e profilaxia de ms |
| US8603978B2 (en) * | 2006-12-01 | 2013-12-10 | The United States of America, as represented by the Secretary, Department of Health and Humand Services | Use of muramyl dipeptide (MDP) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2442832T3 (pl) | 2015-01-30 |
| EP2442832A1 (en) | 2012-04-25 |
| IL216993A (en) | 2016-03-31 |
| JP2012530132A (ja) | 2012-11-29 |
| DK2442832T3 (da) | 2014-11-10 |
| JP5646617B2 (ja) | 2014-12-24 |
| IN2012DN00167A (enExample) | 2015-04-17 |
| AU2010260585A8 (en) | 2012-06-14 |
| US20100317589A1 (en) | 2010-12-16 |
| CN102458476B (zh) | 2014-08-20 |
| ES2521565T3 (es) | 2014-11-12 |
| HK1167101A1 (en) | 2013-02-01 |
| NZ577731A (en) | 2010-08-27 |
| EP2442832B1 (en) | 2014-08-06 |
| IL216993A0 (en) | 2012-02-29 |
| SI2442832T1 (sl) | 2014-12-31 |
| PT2442832E (pt) | 2014-11-11 |
| AU2010260585B2 (en) | 2013-02-21 |
| WO2010147484A8 (en) | 2012-07-19 |
| EP2442832A4 (en) | 2013-07-03 |
| MX2011013661A (es) | 2012-05-22 |
| CY1115714T1 (el) | 2017-01-25 |
| HRP20141035T1 (hr) | 2014-12-19 |
| WO2010147484A1 (en) | 2010-12-23 |
| SMT201400165B (it) | 2015-01-15 |
| CA2688766C (en) | 2015-06-30 |
| US8389479B2 (en) | 2013-03-05 |
| CN102458476A (zh) | 2012-05-16 |
| CA2688766A1 (en) | 2010-12-16 |
| AU2010260585A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1009606A2 (pt) | método para tratamento da esclerose múltipla, método para o tratamento dos sintomas da esclerose múltipla, e, dipeptídeo muramil reticulado em uma micropartícula ou uma composição | |
| BRPI1014824A2 (pt) | composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo | |
| BRPI0911757A2 (pt) | composiÇÕes e mÉtodos para tratar distérbios digestivos. | |
| BRPI0911612A2 (pt) | composições e métodos para o tratamento da esclerose múltipla. | |
| BRPI0815283A2 (pt) | Equipamento para o tratamento da biomassa, método para o tratamento da biomassa, biomassa tratada e hidrolisado | |
| BRPI1008974A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3 | |
| BRPI0920326A2 (pt) | composição e método para tratamento da síndrome do olho ressecado | |
| BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
| BRPI0815387A2 (pt) | composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição | |
| BRPI0810806A2 (pt) | Método para tratar uma lesão cutânea em um indivíduo | |
| BRPI0818732A2 (pt) | Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais. | |
| BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
| BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
| IL218257A (en) | A solid pharmaceutical preparation containing sglt-2 inhibitor and metformin and this drug for the treatment of metabolic disorders | |
| BRPI0922301A2 (pt) | combinações de inibidor de hsp90 | |
| BR112013026341A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia | |
| HUE054298T2 (hu) | Készítmények és módszerek stroke kezelésére egy konkomittáns sztatin terápián tartott alanyban | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| PT2170055T (pt) | Composição para utilização no tratamento de lesão do tecido conjuntivo | |
| BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
| BRPI0820967A2 (pt) | Uso de uma composição, composição farmacêutica e método para tratamento, melhora ou profilaxia dos sintomas de uma doença inflamatória | |
| BRPI1000030A2 (pt) | métodos para tratar esclerose múltipla em um paciente, para aumentar a capacidade de caminhar, para tratar os sintomas da esclerose múltipla, e, composição. | |
| BRPI0919759A2 (pt) | polipeptídeos para tratamento e prevenção de adesões | |
| EP2190408A4 (en) | ANALGETIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHOD FOR THE TREATMENT, PREVENTION OR TREATMENT OF PAIN AND IGNITION | |
| BRPI0822349A2 (pt) | composições e métodos para tratar doenças lisossômicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |